CTKB
Income statement / Annual
Last year (2024), Cytek Biosciences, Inc.'s total revenue was $200.45 M,
an increase of 3.85% from the previous year.
In 2024, Cytek Biosciences, Inc.'s net income was -$6.02 M.
See Cytek Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$200.45 M |
$193.02 M |
$164.04 M |
$127.95 M |
$92.84 M |
$57.88 M |
| Cost of Revenue |
$89.35 M
|
$83.59 M
|
$63.06 M
|
$48.81 M
|
$41.13 M
|
$29.21 M
|
| Gross Profit |
$111.11 M
|
$109.43 M
|
$100.97 M
|
$79.14 M
|
$51.71 M
|
$28.67 M
|
| Gross Profit Ratio |
0.55
|
0.57
|
0.62
|
0.62
|
0.56
|
0.5
|
| Research and Development Expenses |
$39.40 M
|
$44.15 M
|
$34.86 M
|
$24.44 M
|
$13.69 M
|
$8.93 M
|
| General & Administrative Expenses |
$43.11 M
|
$43.97 M
|
$34.69 M
|
$20.84 M
|
$9.37 M
|
$6.74 M
|
| Selling & Marketing Expenses |
$49.11 M
|
$49.15 M
|
$33.23 M
|
$24.71 M
|
$14.99 M
|
$10.24 M
|
| Selling, General & Administrative Expenses |
$92.23 M
|
$93.12 M
|
$67.92 M
|
$45.55 M
|
$24.36 M
|
$16.98 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.02 M
|
| Operating Expenses |
$131.63 M
|
$137.27 M
|
$102.78 M
|
$69.99 M
|
$38.05 M
|
$45.93 M
|
| Cost And Expenses |
$220.98 M
|
$220.86 M
|
$165.84 M
|
$118.79 M
|
$79.18 M
|
$75.14 M
|
| Interest Income |
$10.36 M
|
$6.41 M
|
$4.62 M
|
$49.00 K
|
$110.00 K
|
$711.00 K
|
| Interest Expense |
$0.00
|
$2.07 M
|
$2.57 M
|
$1.74 M
|
$333.00 K
|
$1.00 K
|
| Depreciation & Amortization |
$10.49 M
|
$9.23 M
|
$5.66 M
|
$1.24 M
|
$603.00 K
|
$309.00 K
|
| EBITDA |
-$10.03 M |
-$4.41 M |
$9.49 M |
$8.92 M |
$15.37 M |
-$15.98 M |
| EBITDA Ratio |
-0.05
|
-0.02
|
0.06
|
0.07
|
0.17
|
-0.28
|
| Operating Income Ratio |
-0.1
|
-0.14
|
-0.01
|
0.07
|
0.15
|
-0.3
|
| Total Other Income/Expenses Net |
$14.82 M
|
$12.14 M
|
$3.06 M
|
-$3.22 M
|
$771.00 K
|
$962.00 K
|
| Income Before Tax |
-$5.70 M
|
-$15.71 M
|
$1.26 M
|
$5.94 M
|
$14.43 M
|
-$16.29 M
|
| Income Before Tax Ratio |
-0.03
|
-0.08
|
0.01
|
0.05
|
0.16
|
-0.28
|
| Income Tax Expense |
$320.00 K
|
-$3.56 M
|
-$1.22 M
|
$2.91 M
|
-$4.98 M
|
$533.00 K
|
| Net Income |
-$6.02 M
|
-$12.15 M
|
$2.58 M
|
$3.00 M
|
$19.41 M
|
-$16.83 M
|
| Net Income Ratio |
-0.03
|
-0.06
|
0.02
|
0.02
|
0.21
|
-0.29
|
| EPS |
-0.046 |
-0.0898 |
0.0192 |
0.033 |
0.0242 |
-0.13 |
| EPS Diluted |
-0.0461 |
-0.0898 |
0.0186 |
0.033 |
0.0242 |
-0.13 |
| Weighted Average Shares Out |
$130.61 M
|
$135.28 M
|
$134.51 M
|
$133.75 M
|
$132.99 M
|
$132.99 M
|
| Weighted Average Shares Out Diluted |
$130.61 M
|
$135.28 M
|
$138.56 M
|
$133.75 M
|
$132.99 M
|
$132.99 M
|
| Link |
|
|
|
|
|
|
